History of the Technology
The search for solutions aimed at restoring the balance between the sympathetic and parasympathetic divisions of the autonomic nervous system has been conducted in Russia since the early 1970s. Addressing this issue was necessary to facilitate astronauts' adaptation to long-term stays on space stations and to prevent problems associated with increased sympathetic tone.

The use of medications in space is not always possible, as their effects in zero gravity are difficult to predict. Therefore, under the guidance of Professor Roman Baevsky, Doctor of Medical Sciences, a world-renowned specialist in aviation and space cardiology and circulation physiology under extreme conditions, the development of hardware methods for correcting sympathetic tone began.
Roman Baevsky
Professor, Doctor of Medical Sciences
This work took over a quarter of a century and was successfully completed. It was proven that influencing the balance of the autonomic nervous system using electrical impulses is possible. Another ten years were required to develop a universal, compact, and reliable device suitable for use in any conditions. A significant contribution to this work was made by medical engineer Alexander Gurov, one of the founders of the company "Inferum" and the creator of many unique electronic medical devices.
Alexander Gurov
Medical engineer Alexander Gurov, one of the founders of the company "Inferum"
The method of treating arterial hypertension using medium- and low-frequency electrical impulses, as well as the technology for creating the device for this purpose, were patented in 2014−2015. Vladislav Ivanov, Candidate of Technical Sciences and Chairman of the Board of Directors of the Inferum Group of Companies, organized the serial production of the ABP-051 at its own factory in the city of Kamensk-Uralsky, certified according to the international standard ISO 13 485. Since 2016, the ABP-051 has been widely used worldwide for blood pressure correction.
Vladislav Ivanov
Chairman of the Board of Directors of the "Inferum" Group of Companies
During research on the ABP-051 device (in the early 2000s), it was observed that patients using this technology experienced reduced blood sugar levels and improved blood rheology. To enhance this effect, a specific sequence of neuro-like electrical impulses affecting metabolic processes was developed and tested.

Scientific work continues worldwide to expand the device's range of applications and integrate it into comprehensive treatment methods for conditions related to increased sympathetic tone.
This device has contraindications! Before use, carefully read the instruction manual.
9874